Oral Anticoagulant Therapy in Patients Receiving Haemodialysis: Is It Time to Abandon It?

Oral anticoagulant (OAC) therapy in haemodialysis patients causes a great deal of controversy. This is because a number of pro- and anticoagulant factors play an important role in end-stage renal failure due to the nature of the disease itself. In these conditions, the pharmacokinetic and pharmacody...

Descripción completa

Detalles Bibliográficos
Autores principales: Saracyn, Marek, Brodowska-Kania, Dorota, Niemczyk, Stanisław
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863463/
https://www.ncbi.nlm.nih.gov/pubmed/24379737
http://dx.doi.org/10.1155/2013/170576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863463/
https://www.ncbi.nlm.nih.gov/pubmed/24379737
http://dx.doi.org/10.1155/2013/170576

Ejemplares similares